Q-omics provides the consensus-scored ZNF91 profile across patient tissues and cancer cell-line models. ZNF91 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF91 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, ZNF91 RNA expression shows 21,783 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, and THYM as cancer lineages where ZNF91 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF91 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF91 survival associations across molecular data types. ZNF91 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF91 RNA expression–survival associations across cancer types. High ZNF91 expression shows unfavorable associations in LIHC, but favorable associations in KIRC, BLCA, READ, UCS and ACC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF91 RNA expression.
This table summarizes ZNF91 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF91. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF91 shows lower tumor expression in THCA, KIRC, COAD and HNSC and higher tumor expression in LIHC and BRCA. The LIHC box plot shows higher ZNF91 RNA expression in tumor versus normal tissue (log2 FC = +0.933, t-test p < 0.001).
This table shows molecular features associated with ZNF91 in patient tissues and cancer cell lines. In patient samples, ZNF91 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF91 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
